IgG4-related Disease
22
7
8
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 22 trials
100.0%
+13.4% vs benchmark
9%
2 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (22)
A Study of Efgartigimod in Patients With IgG4-Related Disease
A Study of IMM0306 in IgG4-Related Disease
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related Disease
Short-term Glucocorticoid Combined with MMF for IgG4-RD
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
Study of Sirolimus in IgG4-related Disease
Tofatib Treatment for IgG4-related Disease
Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis
Safety and Efficacy of Abatacept in IgG4-Related Disease
Characterizing IgG4-RD With 68Ga-FAPI PET/CT
Belimumab Treatment for IgG4-related Disease
Treatment of IgG4-Related Disease With Revlimid and Rituximab
Meir Medical Center Rheumatologic Biobank
Infraorbital Nerve Involvement on Magnetic Resonance Imaging in IgG4-related Ophthalmic Disease
To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom
Plasmablast Detection From IgG4-Related Disease Patients
A Laboratory Scan of Patients With Aortic Aneurysms to IgG4 Levels in the Blood
A Prospective Cohort Study of IgG4RD in China